Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication

Journal of General Virology

Volumn 83, Issue 6, 2002, Pages 1353-1359

  Craigo, Jodi K ^a   Leroux, Caroline ^a   Howe, Laryssa ^a   Steckbeck, Jonathan D ^a   Cook, Sheila J ^a   Issel, Charles J ^a   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLYCOPROTEIN GP 90; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY SPECIFICITY; ANTIGENICITY; ARTICLE; CHIMERA; CONTROLLED STUDY; EQUINE INFECTIOUS ANEMIA VIRUS; GENE DELETION; GENETIC VARIABILITY; HORSE DISEASE; HOST; IMMUNITY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LENTIVIRINAE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROVIRUS; STEADY STATE; SYMPTOMATOLOGY; VIRUS CARRIER; VIRUS ENVELOPE; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; EQUUS CABALLUS; LENTIVIRUS; RNA VIRUSES;

EID: 0036274048     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-83-6-1353     Document Type: Article

References (33)

1. Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies
2. Dexamethasone inhibits the early steps of antigen receptor signaling in activated T lymphocytes
3. Structured treatment interruption
4. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies
5. SF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation
6. Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats
7. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process
8. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus
9. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids
10. Evaluation of delayed hypersensitivity responses in normal horses and immunodeficient foals
11. Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: Epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies
12. Antigenic mapping of the envelope proteins of equine infectious anemia virus: Identification of a neutralization domain and a conserved region on glycoprotein 90
13. Transmission of equine infectious anemia virus from horses without clinical signs of disease
14. Development of specific in vitro lymphocyte stimulation responses in horses infected with equine infectious anemia virus
15. Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs
16. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony
17. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies
18. Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus
19. Control of SIV rebound through structured treatment interruptions during early infection
20. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection
21. Equine Retroviruses
22. Course and extent of variation of equine infectious anemia virus during parallel persistent infections
23. Antigenic variation and lentivirus persistence: Variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV
24. Localization of conserved and variable antigenic domains of equine infectious anemia virus envelope glycoproteins using recombinant env-encoded protein fragments produced in Escherichia coli
25. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
26. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection
27. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV)
28. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1
29. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS
30. Identification of hypervariable and conserved regions in the surface envelope gene in the bovine lentivirus
31. + T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses
32. Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anaemia virus during febrile episodes in an experimentally infected horse